LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications
ABSTRACT Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligr...
Gespeichert in:
Veröffentlicht in: | The FASEB journal 2005-05, Vol.19 (7), p.801-803 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 803 |
---|---|
container_issue | 7 |
container_start_page | 801 |
container_title | The FASEB journal |
container_volume | 19 |
creator | Darby, Richard A. J Hine, Anna V |
description | ABSTRACT
Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligram quantities of DNA are required per dose. Previous affinity approaches have involved triplex DNA formation and a sequence‐specific zinc finger protein. We present a more generically applicable protein‐based approach, which exploits the lac operator, present in a wide diversity of plasmids, as a target sequence. We used a GFP/His‐tagged LacI protein, which is precomplexed with the plasmid, and the resulting complex was immobilized on a solid support (TALON resin). Ensuing elution gives plasmid DNA, in good yield (>80% based on recovered starting material, 35–50% overall process), free from detectable RNA and protein and with minimal genomic DNA contamination. Such an affinity‐based process should enhance plasmid purity and ultimately, after appropriate development, may simplify the biomanufacturing process of therapeutic plasmids. |
doi_str_mv | 10.1096/fj.04-2812fje |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67794990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67794990</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397E-b153cedaf1fe3c8c14bf49ee57673b93a9a2c4ca7fd5c12bb5e6fcda04f5f9f73</originalsourceid><addsrcrecordid>eNqFkEFv1DAQhS0EotvCkSvkxM1lHDtOzK2UXWi1gkPp2XKcGfAquwl2IrT_Hq82Um9wGs3oe09vHmNvBFwLMPoD7a5B8bIRJe3wGVuJSgLXjYbnbAWNKbnWsrlglyntAECA0C_ZhahqncVmxdzW-Tu-xy64Cbsi4e8ZDx55GtEHCr5wROEQpmMxzvF0cFMYDsVAxdi7tA9d8fnbTUFDLKZfGN2I83QSjWO_oOkVe0GuT_h6mVfscbP-cfuVb79_ubu92XIvTb3mbQ7usXMkCKVvvFAtKYOYk9ayNdIZV3rlXU1d5UXZthVq8p0DRRUZquUVe3_2HeOQn0iT3Yfkse_dAYc5WV3XRhkD_wVFrTIodAb5GfRxSCki2TGGvYtHK8Ceyre0s6DsUn7m3y7Gc5sbfaKXtjPw8Qz8CT0e_-1mNw-fys09qNO-uV9n8buzmNxg3c8Ykn18KEFIAGNKUFr-BfF-ni4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17494916</pqid></control><display><type>article</type><title>LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Darby, Richard A. J ; Hine, Anna V</creator><creatorcontrib>Darby, Richard A. J ; Hine, Anna V</creatorcontrib><description>ABSTRACT
Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligram quantities of DNA are required per dose. Previous affinity approaches have involved triplex DNA formation and a sequence‐specific zinc finger protein. We present a more generically applicable protein‐based approach, which exploits the lac operator, present in a wide diversity of plasmids, as a target sequence. We used a GFP/His‐tagged LacI protein, which is precomplexed with the plasmid, and the resulting complex was immobilized on a solid support (TALON resin). Ensuing elution gives plasmid DNA, in good yield (>80% based on recovered starting material, 35–50% overall process), free from detectable RNA and protein and with minimal genomic DNA contamination. Such an affinity‐based process should enhance plasmid purity and ultimately, after appropriate development, may simplify the biomanufacturing process of therapeutic plasmids.</description><identifier>ISSN: 0892-6638</identifier><identifier>EISSN: 1530-6860</identifier><identifier>DOI: 10.1096/fj.04-2812fje</identifier><identifier>PMID: 15760969</identifier><language>eng</language><publisher>United States</publisher><subject>Bacterial Proteins - genetics ; DNA - isolation & purification ; DNA vaccines ; Gene Expression ; gene therapy ; Genetic Therapy ; Genetic Vectors ; Green Fluorescent Proteins - genetics ; Histidine - genetics ; Lac Operon - genetics ; lac repressor protein ; Lac Repressors ; Mutation ; Plasmids - genetics ; protein-DNA interactions ; Recombinant Fusion Proteins ; Repressor Proteins - genetics ; Vaccines, DNA</subject><ispartof>The FASEB journal, 2005-05, Vol.19 (7), p.801-803</ispartof><rights>FASEB</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397E-b153cedaf1fe3c8c14bf49ee57673b93a9a2c4ca7fd5c12bb5e6fcda04f5f9f73</citedby><cites>FETCH-LOGICAL-c397E-b153cedaf1fe3c8c14bf49ee57673b93a9a2c4ca7fd5c12bb5e6fcda04f5f9f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1096%2Ffj.04-2812fje$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1096%2Ffj.04-2812fje$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15760969$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Darby, Richard A. J</creatorcontrib><creatorcontrib>Hine, Anna V</creatorcontrib><title>LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications</title><title>The FASEB journal</title><addtitle>FASEB J</addtitle><description>ABSTRACT
Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligram quantities of DNA are required per dose. Previous affinity approaches have involved triplex DNA formation and a sequence‐specific zinc finger protein. We present a more generically applicable protein‐based approach, which exploits the lac operator, present in a wide diversity of plasmids, as a target sequence. We used a GFP/His‐tagged LacI protein, which is precomplexed with the plasmid, and the resulting complex was immobilized on a solid support (TALON resin). Ensuing elution gives plasmid DNA, in good yield (>80% based on recovered starting material, 35–50% overall process), free from detectable RNA and protein and with minimal genomic DNA contamination. Such an affinity‐based process should enhance plasmid purity and ultimately, after appropriate development, may simplify the biomanufacturing process of therapeutic plasmids.</description><subject>Bacterial Proteins - genetics</subject><subject>DNA - isolation & purification</subject><subject>DNA vaccines</subject><subject>Gene Expression</subject><subject>gene therapy</subject><subject>Genetic Therapy</subject><subject>Genetic Vectors</subject><subject>Green Fluorescent Proteins - genetics</subject><subject>Histidine - genetics</subject><subject>Lac Operon - genetics</subject><subject>lac repressor protein</subject><subject>Lac Repressors</subject><subject>Mutation</subject><subject>Plasmids - genetics</subject><subject>protein-DNA interactions</subject><subject>Recombinant Fusion Proteins</subject><subject>Repressor Proteins - genetics</subject><subject>Vaccines, DNA</subject><issn>0892-6638</issn><issn>1530-6860</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEFv1DAQhS0EotvCkSvkxM1lHDtOzK2UXWi1gkPp2XKcGfAquwl2IrT_Hq82Um9wGs3oe09vHmNvBFwLMPoD7a5B8bIRJe3wGVuJSgLXjYbnbAWNKbnWsrlglyntAECA0C_ZhahqncVmxdzW-Tu-xy64Cbsi4e8ZDx55GtEHCr5wROEQpmMxzvF0cFMYDsVAxdi7tA9d8fnbTUFDLKZfGN2I83QSjWO_oOkVe0GuT_h6mVfscbP-cfuVb79_ubu92XIvTb3mbQ7usXMkCKVvvFAtKYOYk9ayNdIZV3rlXU1d5UXZthVq8p0DRRUZquUVe3_2HeOQn0iT3Yfkse_dAYc5WV3XRhkD_wVFrTIodAb5GfRxSCki2TGGvYtHK8Ceyre0s6DsUn7m3y7Gc5sbfaKXtjPw8Qz8CT0e_-1mNw-fys09qNO-uV9n8buzmNxg3c8Ykn18KEFIAGNKUFr-BfF-ni4</recordid><startdate>200505</startdate><enddate>200505</enddate><creator>Darby, Richard A. J</creator><creator>Hine, Anna V</creator><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7X8</scope></search><sort><creationdate>200505</creationdate><title>LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications</title><author>Darby, Richard A. J ; Hine, Anna V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397E-b153cedaf1fe3c8c14bf49ee57673b93a9a2c4ca7fd5c12bb5e6fcda04f5f9f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Bacterial Proteins - genetics</topic><topic>DNA - isolation & purification</topic><topic>DNA vaccines</topic><topic>Gene Expression</topic><topic>gene therapy</topic><topic>Genetic Therapy</topic><topic>Genetic Vectors</topic><topic>Green Fluorescent Proteins - genetics</topic><topic>Histidine - genetics</topic><topic>Lac Operon - genetics</topic><topic>lac repressor protein</topic><topic>Lac Repressors</topic><topic>Mutation</topic><topic>Plasmids - genetics</topic><topic>protein-DNA interactions</topic><topic>Recombinant Fusion Proteins</topic><topic>Repressor Proteins - genetics</topic><topic>Vaccines, DNA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Darby, Richard A. J</creatorcontrib><creatorcontrib>Hine, Anna V</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The FASEB journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Darby, Richard A. J</au><au>Hine, Anna V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications</atitle><jtitle>The FASEB journal</jtitle><addtitle>FASEB J</addtitle><date>2005-05</date><risdate>2005</risdate><volume>19</volume><issue>7</issue><spage>801</spage><epage>803</epage><pages>801-803</pages><issn>0892-6638</issn><eissn>1530-6860</eissn><abstract>ABSTRACT
Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligram quantities of DNA are required per dose. Previous affinity approaches have involved triplex DNA formation and a sequence‐specific zinc finger protein. We present a more generically applicable protein‐based approach, which exploits the lac operator, present in a wide diversity of plasmids, as a target sequence. We used a GFP/His‐tagged LacI protein, which is precomplexed with the plasmid, and the resulting complex was immobilized on a solid support (TALON resin). Ensuing elution gives plasmid DNA, in good yield (>80% based on recovered starting material, 35–50% overall process), free from detectable RNA and protein and with minimal genomic DNA contamination. Such an affinity‐based process should enhance plasmid purity and ultimately, after appropriate development, may simplify the biomanufacturing process of therapeutic plasmids.</abstract><cop>United States</cop><pmid>15760969</pmid><doi>10.1096/fj.04-2812fje</doi><tpages>3</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0892-6638 |
ispartof | The FASEB journal, 2005-05, Vol.19 (7), p.801-803 |
issn | 0892-6638 1530-6860 |
language | eng |
recordid | cdi_proquest_miscellaneous_67794990 |
source | MEDLINE; Access via Wiley Online Library; Alma/SFX Local Collection |
subjects | Bacterial Proteins - genetics DNA - isolation & purification DNA vaccines Gene Expression gene therapy Genetic Therapy Genetic Vectors Green Fluorescent Proteins - genetics Histidine - genetics Lac Operon - genetics lac repressor protein Lac Repressors Mutation Plasmids - genetics protein-DNA interactions Recombinant Fusion Proteins Repressor Proteins - genetics Vaccines, DNA |
title | LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A51%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LacI-mediated%20sequence-specific%20affinity%20purification%20of%20plasmid%20DNA%20for%20therapeutic%20applications&rft.jtitle=The%20FASEB%20journal&rft.au=Darby,%20Richard%20A.%20J&rft.date=2005-05&rft.volume=19&rft.issue=7&rft.spage=801&rft.epage=803&rft.pages=801-803&rft.issn=0892-6638&rft.eissn=1530-6860&rft_id=info:doi/10.1096/fj.04-2812fje&rft_dat=%3Cproquest_cross%3E67794990%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17494916&rft_id=info:pmid/15760969&rfr_iscdi=true |